Designer Exosomes: How Engineered Vesicles Are Transforming Drug Delivery in 2027

In the evolving landscape of biomedical innovation, exosomes have emerged as one of the most promising tools for next-generation therapies. These nanoscale, membrane-bound vesicles, naturally secreted...

bioinformant.com

How Human iPSCs are Revolutionizing Drug Discovery in 2027

Researchers can now produce human iPSCs and differentiate them into different cell types to support drug discovery and development efforts.

bioinformant.com

Rose BioSolutions Debuts as Latest CGT CDMO Following GI Partners' Acquisition of Charles River Businesses | BioInformant

The cell and gene therapy (CGT) contract manufacturing landscape has a new market entrant, and it’s a big one. On May 7, 2026, San Francisco-based private investment firm GI Partners announced that it...

bioinformant.com

Aspen Advances iPSC-Based Therapy for Parkinson’s Toward Phase 3

Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in “Cell Stem Cell” Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and prec...

bioinformant.com

How Human iPSCs are Revolutionizing Drug Discovery in 2027

Researchers can now produce human iPSCs and differentiate them into different cell types to support drug discovery and development efforts.

bioinformant.com

I Peace Selected as a TOP 10 Awardee for the "Top 10 Longevity Breakthrough Awards 2026" | BioInformant

NEWS PROVIDED BY I Peace, Inc., Oct 1, 2026, 09:01 ET PALO ALTO, Calif., Oct. 1, 2026 — I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPS cell) technologies for regenerativ...

bioinformant.com

Anja Health Makes Cord Blood, Cord Tissue and Placenta Banking an Employee Benefit and Invites Other Employers to Join In | BioInformant

Anja Health is offering stem cell banking as an employee benefit and inviting employers to bring cord blood, cord tissue and placenta banking to their teams. LOS ANGELES , CA, UNITED STATES, September...

bioinformant.com

Cord Blood Industry Consolidation Escalates in 2026 | BioInformant

The cord blood industry had strong growth during the early 2000's. However, the market has matured and consolidated over the past decade.

bioinformant.com

Cryopraxis, BioNK and Radboudumc Partner to Transfer Cord Blood-Derived NK Cell Technology to Brazil | BioInformant

Agreement establishes a phased technology-transfer program for the RNK001/HSPC-NK platform and creates a framework for future CAR-NK development SÃO PAULO, Brazil and NIJMEGEN, the Netherlands — Septe...

bioinformant.com

MUSE Cells Now Available at Longevity Medical Institute® | BioInformant

As part of its Regenerative Neurology Program, Longevity Medical Institute® is making MUSE cell therapy available to select patients, using cells produced in-house at the Institute’s biotechnology lab...

bioinformant.com

Greenstone Biosciences Wins Breakthrough T1D Grant to Model Diabetes Using Patient-Derived iPSCs | BioInformant

Greenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell Platform PALO ALTO, Calif. –Greenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Pa...

bioinformant.com

New Book "The Language of Healing" Tackles the Patient Education Gap in Regenerative Medicine | BioInformant

The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely thro...

bioinformant.com

IPS HEART's iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone | BioInformant

IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies HOUSTON–IPS HEART, Inc., a biopharmaceutical company pioneer...

bioinformant.com

Cell Therapy CDMO Cellipont Bioservices Celebrates Major Manufacturing Milestone: Releases 100th GMP Batch | BioInformant

Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility THE WOODLANDS, Texas, July 28, 2026 — Cellipont Bioservices, a cell...

bioinformant.com

Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD | BioInformant

SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD0...

bioinformant.com

Top Companies Developing Cell Therapies For Diabetes in 2026

Due to advances in regenerative medicine, these companies are leading the charge to find cell therapies for the treatment for diabetes.

bioinformant.com

The Pipeline for of iPSC-Derived Cell Therapeutics in 2026

While iPSCs are commonly used in drug discovery, we remain in the early stages of using iPSC-derived cell therapeutics in humans.

bioinformant.com

China's First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing | BioInformant

For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for comm...

bioinformant.com

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel | BioInformant

New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 — Kyverna Therapeut...

bioinformant.com

Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform | BioInformant

Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration. SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, M...

bioinformant.com

MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis | BioInformant

U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-...

bioinformant.com

Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance | BioInformant

CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has bee...

bioinformant.com

Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation | BioInformant

The companies will generate data using Applied StemCell’s induced pluripotent stem cell technologies and Syntax Bio’s Cellgorithm™ platform to support application discovery and development CHICAGO & M...

bioinformant.com

Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies | BioInformant

MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, an...

bioinformant.com

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy | BioInformant

SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic...

bioinformant.com

Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain | BioInformant

ALTAMONTE SPRINGS, Fla. — In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment...

bioinformant.com

RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions | BioInformant

Partnership pairs Applied StemCell’s induced pluripotent stem cell technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems to accelerate development and manufacturing ...

bioinformant.com

BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients | BioInformant

BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advan...

bioinformant.com